Swash M, Roberts A H, Zakko H, Heathfield K W
J Neurol Neurosurg Psychiatry. 1972 Apr;35(2):186-91. doi: 10.1136/jnnp.35.2.186.
Seventeen patients with choreiform, athetoid, or ballistic involuntary movements, or with spasmodic torticollis, were treated with tetrabenazine in doses of 25 to 200 mg daily for periods varying from two weeks to more than six months. Randomized ciné film of the patients' involuntary movements, taken before, during, and after treatment was assessed individually by seven `blind' observers. Eight patients were judged improved; two had Huntington's chorea, two athetosis, two dystonia musculorum deformans, one hemiballismus, and one spasmodic torticollis. Four of the eight improved patients have continued taking the drug for longer than six months. In a second study seven patients with Huntington's chorea were treated for two weeks each with tetrabenazine (50 mg t.d.s.) and with amantadine (100 mg t.d.s.) and the results assessed by the same method. The choreiform movements of six of these patients were strikingly improved with tetrabenazine therapy, but amantadine had no effect. Tetrabenazine is an effective agent for the suppression of choreiform and ballistic involuntary movements. It is only slightly effective in the treatment of athetosis and spasmodic torticollis. Drowsiness, insomnia, and depression were the most conspicuous unwanted effects, and these may limit the clinical usefulness of the drug.
17例患有舞蹈样动作、手足徐动症或投掷样不自主运动,或痉挛性斜颈的患者,接受了丁苯那嗪治疗,剂量为每日25至200毫克,治疗时间从两周至六个多月不等。在治疗前、治疗期间和治疗后拍摄了患者不自主运动的随机电影,由7名“不知情”的观察者分别进行评估。8名患者被判定有所改善;其中2例患有亨廷顿舞蹈症,2例患有手足徐动症,2例患有变形性肌张力障碍,1例患有偏身投掷症,1例患有痉挛性斜颈。8名病情改善的患者中有4人持续服药超过6个月。在第二项研究中,7例亨廷顿舞蹈症患者分别接受了为期两周的丁苯那嗪(每日3次,每次50毫克)和金刚烷胺(每日3次,每次100毫克)治疗,并采用相同方法评估结果。丁苯那嗪治疗使其中6例患者的舞蹈样动作显著改善,但金刚烷胺无效。丁苯那嗪是一种抑制舞蹈样和投掷样不自主运动的有效药物。它在治疗手足徐动症和痉挛性斜颈方面效果甚微。嗜睡、失眠和抑郁是最明显的不良反应,这些可能会限制该药物的临床应用。